# US 2019/0376152 A1 · Detection of nucleic acids from multiple types of human papillomavirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376152 A1
- Document ID: US20190376152A1
- Status: Published application
- Kind: A1
- Application number: 16/551,927
- Filed: 2019-08-27
- Published: 2019-12-12
- Earliest claimed: 2004-12-08
- Assignees: Gen-Probe Incorporated
- Applicants: Gen-Probe Incorporated
- Inventors: Sylvia A. NORMAN; Jennifer J. BUNGO; William L. HANNA; Neeraj P. RAO
- Web page: https://patentgrep.com/patent/US20190376152A1

## CPC

- C12Q 1/708: {for papilloma}
- C07K 14/005: from viruses
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.

## Claims

### Claim 1

A combination of oligomers for detecting human papillomavirus (HPV) types in group A2, the combination comprising:
a first amplification oligomer comprising a target-specific sequence and a 5′ promoter sequence, wherein the first amplification oligomer target-specific sequence consists of SEQ ID NO:25 or SEQ ID NO:27, or an RNA equivalent thereof; and
a second amplification oligomer comprising a target-specific sequence consisting of SEQ ID NO:38, or an RNA equivalent thereof.

### Claim 2 (depends on 1)

The oligomer combination of claim 1, wherein the nucleotide sequence of the first amplification oligomer consists of SEQ ID NO:24 or SEQ ID NO:26, or an RNA equivalent thereof.

### Claim 3 (depends on 1)

The oligomer combination of claim 1, wherein the first amplification oligomer target-specific sequence consists of SEQ ID NO:25, or an RNA equivalent thereof.

### Claim 4 (depends on 3)

The oligomer combination of claim 3, further comprising a third amplification oligomer comprising a target-specific sequence and a 5′ promoter sequence, wherein the third amplification oligomer target-specific sequence consists of SEQ ID NO:27, or an RNA equivalent thereof.

### Claim 5 (depends on 4)

The oligomer combination of claim 4, wherein
the nucleotide sequence of the first amplification oligomer consists of SEQ ID NO:24, or an RNA equivalent thereof, and
the nucleotide sequence of the third amplification oligomer consists of SEQ ID NO:26, or an RNA equivalent thereof.

### Claim 6 (depends on 1)

The oligomer combination of claim 1, further comprising a detection probe oligomer comprising a target-specific sequence selected from the group consisting of SEQ ID NO:12, a complement thereof, and an RNA equivalent thereof.

### Claim 7 (depends on 6)

The oligomer combination of claim 6, wherein the detection probe oligomer further comprises a detectable label.

### Claim 8 (depends on 6)

The oligomer combination of claim 6, wherein the detection probe oligomer target-specific sequence comprises at least one 2′-methoxy RNA group.

### Claim 9 (depends on 1)

The oligomer combination of claim 1, wherein the oligomer combination is contained in an amplification reaction mixture.

### Claim 10 (depends on 6)

The oligomer combination of claim 6, wherein the oligomer combination is contained in an amplified product detection reaction mixture.

### Claim 11 (depends on 1)

The oligomer combination of claim 1, wherein the oligomer combination is contained in a kit.

### Claim 12

A method for of determining the presence or absence of a human papillomavirus (HPV) nucleic acid type in group A2 in a sample, comprising the steps of:
(a) contacting a sample, said sample suspected of containing a target nucleic acid of an HPV type in group A2, with a combination of amplification oligomers that amplify a target region of said target nucleic acid, wherein
(i) a first amplification oligomer comprises a target-specific sequence and a 5′ promoter sequence, wherein the first amplification oligomer target-specific sequence consists of SEQ ID NO:25 or SEQ ID NO:27, or an RNA equivalent thereof; and
(ii) a second amplification oligomer comprises a target-specific sequence consisting of SEQ ID NO:38, or an RNA equivalent thereof;
(b) performing an amplification reaction using the amplification oligomers, wherein if the target nucleic acid of the HPV type in group A2 is present in the sample, an amplification product is produced; and
(c) detecting the amplification product.

### Claim 13 (depends on 12)

The method of claim 12, wherein the first amplification oligomer target-specific sequence consists of SEQ ID NO:25, or an RNA equivalent thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the combination of amplification oligomers further comprises a third amplification oligomer comprising a target-specific sequence and a 5′ promoter sequence, wherein the third amplification oligomer target-specific sequence consists of SEQ ID NO:27, or an RNA equivalent thereof.

### Claim 15 (depends on 12)

The method of claim 12, wherein the detecting step (c) comprises contacting the amplification product, if present, with a detection probe oligomer that binds specifically to the amplification product and results in a signal to indicate the presence in the sample of the HPV nucleic acid type in group A2.

### Claim 16 (depends on 15)

The method of claim 15, wherein the detection probe oligomer comprises a target-specific sequence selected from the group consisting of SEQ ID NO:12, a complement thereof, and an RNA equivalent thereof.

### Claim 17 (depends on 12)

The method of claim 12, further comprising a step of separating any target nucleic acid of the HPV type in group A2 from other components in the sample by (i) contacting the HPV target nucleic acid in the sample with a capture oligomer and (ii) separating a complex that includes the capture oligomer and the HPV target nucleic acid from other sample components before the amplifying step (b).

### Claim 18 (depends on 17)

The method of claim 17, wherein the capture oligomer comprises the target-specific sequence of SEQ ID NO:6 joined to a ligand moiety.

### Claim 19 (depends on 18)

The method of claim 18, wherein the ligand moiety is a substantially homopolymeric tail sequence attached to the 3′ end of the target-specific sequence of SEQ ID NO:6.

### Claim 20 (depends on 12)

The method of claim 12, wherein the amplification reaction of step (b) is a transcription-associated amplification reaction.
